Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

Harpoon Therapeutics, Inc. announced that it has entered into a clinical supply agreement with Roche to supply atezolizumab for use in the Company’s HPN328, a DLL3 targeting TriTAC®, clinical development program.